{'fraction_non_alphanumeric': 0.03508771929824561, 'fraction_numerical': 0.03007518796992481, 'mean_word_length': 5.451612903225806, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Safety of Bifidobacterium breve (BBG‐01) in preterm infants

Since 1982, viable cells of Bifidobacterium breve (BBG‐01) have been used in pediatric patients for clinical conditions such as intractable infantile diarrhea, preterm status, and pediatric surgery. Although the efficacy of BBG‐01 has been widely reported, adverse events related to the use of BBG‐01 have been reported in very few cases.